Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI Floxuridine/Oxaliplatin + Systemic Irinotecan for Colorectal Liver Metastasis
NCT03493061Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine, oxaliplatin and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Primary endpoint: Complete resection rate at 4 months. Started Feb 2018; status: completed.
02
Drugs
floxuridineoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03493061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493061.